科普丨度拉糖肽与司美格鲁肽该怎样选择？

原创 朝阳药师 北京朝阳医院药事部 收录于合集#药物 8 个 #糖尿病 3 个 #GLP-1RA 1 个 #度拉糖肽 1 个 #司美格鲁肽 2 个

新型降糖药物GLP⁃1受体激动剂（GLP⁃1RA）类药物因其降糖疗效、代谢获益以及安全性，获得国内外指南的广泛认可及大众高度关注。其中超长效的GLP⁃1RA 周制剂由于降低了注射频次，提高患者依从性而进一步增加临床使用优势。

前段时间小编为大家讲解了司美格鲁肽的相关知识，有患者提出想了解它与度拉糖肽有何区别。今天小编特意安排了这篇科普作品，希望能帮助更多的患者了解GLP⁃1RA 周制剂。

以下图片可点击放大

向左滑动翻页查看

参考文献

[1] Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin⁃4, an exendin⁃3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas[J]. J Biol Chem, 1992, 267: 7402-7405.

[2] Lovshin JA. Glucagon ⁃like peptide ⁃ 1 receptor agonists: a class update for treating type 2 diabetes[J]. Can J Diabetes, 2017, 41: 524-535.

[3] Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once⁃weekly vs exenatide twice⁃daily in Asian patients with type 2 diabetes mellitus[J]. J Diabetes Investig, 2013, 4: 53⁃61.

[4] Ji LN, Dong XL, Li YM, et al. Efficacy and safety of once⁃weekly semaglutide versus once ⁃daily sitagliptin as add ⁃on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30⁃week, double⁃blind, phase 3a, randomized trial[J]. Diabetes Obes Metab, 2021, 23: 404-414.

[5] Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East⁃Asian patients with type 2 diabetes in a multicentre, double ⁃ blind, randomized, parallel-arm, active comparator, phase III trial[J]. Diabetes Obes Metab, 2018, 20: 2121-2130.

[6] Boye KS, Matza LS, Currie BM, et al. Validity and analysis of the diabetes injection device preference questionnaire(DID⁃PQ)[J]. J Patient Rep Outcomes, 2020, 4: 104.

[7] Matza LS, Boye KS, Stewart KD, et al. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: a crossover study (PREFER)[J]. Diabetes Obes Metab, 2020, 22: 355⁃364.

[8] Asakura T, Suzuki S, Aranishi T, et al. Comparative usability study of the dulaglutide single⁃use pen versus the insulin degludec FlexTouch((R))among self⁃injection⁃naive patients with type 2 diabetes mellitus in Japan[J]. Curr Med Res Opin, 2018, 34: 1117-1124.

[8] 纪立农. 胰高血糖素样肽1受体激动剂周制剂中国证据与专家指导建议[J]. 中国糖尿病杂志, 2022, 30(6): 405-411.

关注百姓用药安全

朝阳药师在您身边出品：北京朝阳医院药事部

作者：郑紫荆

审核：张 征

编辑：刘 莹

责编：杨 婧

主编：安卓玲

注：本文仅用于公益科普，非商用，侵删

字体来源：字体管家方萌（非商业使用）

图片来源：腾讯医典、公开网络等

阅读原文